Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2a, Double-Blind, Randomized, Placebo-Controlled, Crossover Study Evaluating the Safety and Efficacy of Propagermanium in Patients With Primary Focal Segmental Glomerulosclerosis (FSGS) Who Are Receiving Irbesartan

Trial Profile

A Phase 2a, Double-Blind, Randomized, Placebo-Controlled, Crossover Study Evaluating the Safety and Efficacy of Propagermanium in Patients With Primary Focal Segmental Glomerulosclerosis (FSGS) Who Are Receiving Irbesartan

Recruiting
Phase of Trial: Phase II

Latest Information Update: 19 Dec 2018

At a glance

  • Drugs Irbesartan/propagermanium (Primary) ; Propagermanium (Primary) ; Irbesartan
  • Indications Focal segmental glomerulosclerosis
  • Focus Adverse reactions
  • Acronyms ACTION
  • Sponsors Dimerix Bioscience
  • Most Recent Events

    • 13 Sep 2018 Status changed from not yet recruiting to recruiting.
    • 04 Jun 2018 New trial record
    • 15 May 2018 Professor Simon Roger is the principal investigator for the ACTION trials in Focal Segmental Glomerulosclerosis and Diabetic Kidney Disease, according to a Dimerix Bioscience media release. Recruitment is expected to begin in Q3 calendar 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top